The two companies are direct competitors in the diabetes treatment market.
But in 2019, Novo Nordisk issued a press release comparing Novo Nordisk’s drug Tresiba with Sanofi’s Toujeo, which was misleading, the court states.
The judges emphasize that Novo Nordisk also crossed the line in 2017 by issuing an illegal press release, and that Sanofi was also violated at the time.
The Maritime and Commercial Court cannot see mitigating circumstances. As a large global pharmaceutical company, the Danish company must “be assumed to have in-depth knowledge of rules and professional standards in relation to communication of study results”, it is stated in the premises.
Source: The Nordic Page
